Tivozanib in renal cell carcinoma: A systematic review of the evidence and its dissemination in the scientific literature
Tivozanib in renal cell carcinoma: A systematic review of the evidence and its dissemination in the scientific literature
Tivozanib (Fotivda) is an anti-angiogenic tyrosine kinase inhibitor that was denied access to the US market by the Food and Drug Administration (FDA). In contrast, it was granted approval by the European Medicines Agency (EMA) for the treatment of Renal Cell Carcinoma in adults.